Intense Pulsed Light (IPL) therapy is an in-office, drug-free treatment for chronic dry eye disease, particularly evaporative dry eye caused by meibomian gland dysfunction (MGD). At Surgical Eye Experts, Dr. Geoffrey Collett performs IPL using the OptiLight device by Lumenis, the first IPL system FDA 510(k) cleared specifically for the treatment of MGD-associated dry eye. Each session takes about 10 to 15 minutes and treats the skin around the eyes in specific pulse patterns.
Most chronic dry eye is not simply a tear-volume problem; it is an evaporative problem driven by inflammation and blocked meibomian glands along the eyelids. IPL targets the abnormal blood vessels that feed eyelid inflammation, reducing the release of pro-inflammatory mediators that contribute to MGD. During the same appointment, Dr. Collett typically performs manual meibomian gland expression so that the softened, loosened oils can actually flow. This combination - IPL plus expression - is why the protocol works when drops alone do not.
OptiLight uses a proprietary Optimal Pulse Technology that delivers light in a specific wavelength and pulse pattern shown in clinical studies to be effective for MGD-related dry eye. Not all IPL devices are equivalent - generic cosmetic IPL devices are not FDA-cleared for this indication and may use different wavelengths and pulse durations. We use OptiLight specifically because of its dry eye evidence base.
Burning, stinging, or gritty sensation
Paradoxical watery eyes (reflex tearing from surface irritation)
Fluctuating or blurry vision that clears with blinking
Contact lens intolerance
Light sensitivity
Eye fatigue at the end of screen-work days
Rosacea-associated blepharitis
Tears have three layers: a mucin layer against the eye, a water layer, and an outermost lipid layer produced by the meibomian glands along your eyelids. When those glands become blocked, the lipid layer is thin or absent - tears evaporate faster than they can be replenished, and the eye surface dries out even when total tear production is normal. MGD is the underlying cause of most chronic dry eye, and IPL is designed to address MGD specifically. During your workup, Dr. Collett may perform meibography to photograph your glands and confirm the diagnosis.
OptiLight is delivered as a series of four sessions spaced 2 to 4 weeks apart. Most patients notice meaningful symptom improvement after session two, with the full effect observable after session four. Maintenance sessions are typically recommended every 6 to 12 months to sustain the benefit, similar to how a hair or skin IPL protocol works.
IPL is most effective in patients with Fitzpatrick skin types I through IV (fair to medium skin tones). It is not recommended for darker skin types (V-VI) because of a small but real risk of pigmentary changes. Other contraindications include active rosacea flares with open lesions, recent tanning or sun exposure in the treatment zone, active melasma, certain photosensitizing medications (discussed at your consultation), and pregnancy. Patients who are not IPL candidates have other interventional options, including Prokera amniotic membrane, thermal gland expression, scleral contact lenses, cyclosporine or lifitegrast drops, and autologous serum tears.
Dr. Collett approaches dry eye on a treatment ladder rather than one-size-fits-all. Prescription drops and artificial tears address milder cases. IPL plus meibomian gland expression is our workhorse for moderate MGD. For patients with persistent surface damage or corneal breakdown, Prokera (a biologic amniotic membrane device) or CAM360 may be added to restore the ocular surface. The goal is to select the lightest-touch intervention that actually works for your presentation, not to over-treat or under-treat.
LipiFlow uses heat and pressure to unclog meibomian glands in a single in-office session. It works, but it does not address the inflammatory vascular component that IPL targets. Prescription drops (cyclosporine, lifitegrast) reduce surface inflammation but do not unblock glands. IPL + expression addresses both inflammation and gland blockage in the same session, which is why it has become the interventional workhorse for most MGD-driven dry eye.
IPL is generally not covered by medical insurance because it is classified as a non-covered service for dry eye. Most patients pay out-of-pocket for the initial four-session series. CareCredit financing is available. Maintenance sessions every 6 to 12 months are typically priced per visit. Call 281-800-1585 or request a consultation for current pricing.
Dr. Collett performs a complete dry eye workup before recommending IPL - including meibography when appropriate, tear osmolarity, and inflammation markers - so the recommendation is based on your specific diagnosis rather than a generic protocol. Each IPL session is performed by Dr. Collett personally, not delegated to a technician. Single-surgeon continuity means the same physician who diagnosed your MGD is the one treating it and following your response over the four-session series.
The standard OptiLight protocol is four sessions 2 to 4 weeks apart. Maintenance sessions are typically recommended every 6 to 12 months.
Most patients describe each pulse as a quick snap of a rubber band. Cooling gel, corneal shields, and the brief duration make the session tolerable for most patients without anesthesia.
IPL for dry eye is generally not covered by medical insurance. CareCredit financing is available.
IPL targets both eyelid inflammation and gland obstruction. LipiFlow uses heat and pressure to unclog glands but does not address inflammation. Many patients respond better to IPL for this reason.
Most patients experience 6 to 12 months of symptom improvement after the initial four-session series, with maintenance sessions extending the benefit.
Yes. IPL with meibomian gland expression is one of the most effective treatments for MGD-driven evaporative dry eye.
Dry eye is a chronic condition that is managed, not cured. IPL and the interventional dry eye ladder can significantly reduce symptoms and slow progression, but ongoing maintenance and self-care remain important.
IPL is an in-office light treatment for dry eye caused by meibomian gland dysfunction (MGD). Pulses of light applied to the skin around the eyes reduce inflammation and abnormal blood vessels and warm the meibomian glands so they release healthy oil. At Surgical Eye Experts we use OptiLight by Lumenis, the first IPL FDA-approved for dry eye.
Most chronic dry eye comes from blocked meibomian glands that fail to produce the oil layer of your tears. OptiLight IPL reduces inflammation, clears abnormal vessels feeding it, and liquefies hardened oil so the glands flow again, improving tear quality at the source rather than just lubricating the surface like drops do.
IPL targets evaporative dry eye and MGD: burning, grittiness, a foreign-body sensation, fluctuating or blurry vision, light sensitivity, and reflex watering. It is best for inflammatory, gland-related dry eye rather than purely tear-deficient cases. Dr. Collett evaluates your tear film and glands first to confirm IPL is the right treatment for you.
Good candidates have dry eye driven by meibomian gland dysfunction and inflammation that has not responded well to drops or warm compresses. A typical course is four sessions spaced about two to four weeks apart. Because OptiLight uses light on the skin, very dark or recently tanned skin may need adjusted settings, which Dr. Collett reviews at consultation.
Each OptiLight session takes about 10 to 15 minutes. Protective shields cover your eyes, a cooling gel is applied, and brief pulses of light are delivered across the cheeks and around the eyes. Most patients feel a warm snap, not pain. Dr. Collett often expresses the meibomian glands afterward. You return to normal activities immediately.
Call 281-800-1585 or request an appointment online. See also our interventional dry eye hub. Learn more about OptiLight at lumenis.com.